Thryv Therapeutics, Inc.
Nasdaq THRY · Grapevine, TX
Works in Cardiovascular · Genetic & rare · Metabolic & endocrine
Thryv Therapeutics, Inc. is a clinical trial sponsor based in Grapevine, TX, listed as Nasdaq THRY. It has 2 active clinical trials with 284 planned participants, in Cardiovascular, Genetic & rare and Metabolic & endocrine. Since 2021 it has completed 3 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq THRY
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Thryv Therapeutics, Inc
Thryv Therapeutics, Inc is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 284 planned participants, in Cardiovascular, Genetic & rare, Metabolic & endocrine. Since 2021 it has completed 3 trials and stopped 1 early.
Thryv Therapeutics, Inc is based in Grapevine, TX and is listed as Nasdaq THRY. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Thryv Therapeutics, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-08.
Approve Suite is not affiliated with Thryv Therapeutics, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.